SLC5A2 and diabetes mellitus: The patient in Case #1, a nondiabetic patient with cisplatin-induced renal magnesium wasting [26–28], exhibited substantial biochemical improvement after initiation of empagliflozin, highlighting a potential role for SGLT2 inhibition even in the absence of diabetes.